Trevi Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRVI research report →
Companywww.trevitherapeutics.com
Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
- CEO
- Jennifer L. Good
- IPO
- 2019
- Employees
- 31
- HQ
- New Haven, CT, US
Price Chart
Valuation
- Market Cap
- $1.97B
- P/E
- -44.31
- P/S
- 0.00
- P/B
- 11.74
- EV/EBITDA
- -41.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -24.53%
- ROIC
- -30.49%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-42,759,000 · 10.75%
- EPS
- $-0.29 · 38.30%
- Op Income
- $-49,328,000
- FCF YoY
- -9.95%
Performance & Tape
- 52W High
- $16.12
- 52W Low
- $5.38
- 50D MA
- $13.11
- 200D MA
- $11.10
- Beta
- 1.08
- Avg Volume
- 1.52M
Get TickerSpark's AI analysis on TRVI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 19, 26 | Cassella James V | other | 215,000 |
| Feb 19, 26 | Galletta Christopher | other | 35,000 |
| Feb 19, 26 | SCIASCIA THOMAS | other | 85,000 |
| Feb 19, 26 | GOOD JENNIFER L | other | 675,000 |
| Feb 19, 26 | Simon Farrell | other | 160,000 |
| Dec 31, 25 | SANDELL SCOTT D | other | 0 |
| Dec 31, 25 | Florence Anthony A. Jr. | other | 0 |
| Apr 17, 25 | SANDELL SCOTT D | other | 1,851,852 |
| Apr 17, 25 | Florence Anthony A. Jr. | other | 1,851,852 |
| Dec 31, 25 | Behbahani Ali | other | 0 |
Our TRVI Coverage
We haven't published any research on TRVI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TRVI Report →